66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2200058382 | 2018-12-01 | 2022-04-07 | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | IgA Nephropathy | Control group:Losartan potassium and other basic western treatment;Observation group:On the basis of control group, IgA nephropathy I prescription was combined orally;Healthy control group:None; | Hu Qianqian | NULL | Completed | 18 | 65 | Both | Control group:45;Observation group:45;Healthy control group:20; | China | |
2 | ITMCTR2200005824 | 2018-12-01 | 2022-04-07 | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | Influence of IgA Nephropathy ? Prescription on Serum Gd-IgA1 and BAFF level for Patients with IgA Nephropathy | IgA Nephropathy | Control group:Losartan potassium and other basic western treatment;Healthy control group:None;Observation group:On the basis of control group, IgA nephropathy I prescription was combined orally; | HuQianqian | NULL | Completed | 18 | 65 | Both | Control group:45;Healthy control group:20;Observation group:45; | China | |
3 | ChiCTR-IIR-17013487 | 2018-01-01 | 2017-11-22 | A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab | A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab | IgA nephropathy | Experimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab; | The Third Xiangya Hospital of Central South University | NULL | Recruiting | 18 | 70 | Both | Experimental group:36;Control group 1:36;Control group 2:36; | 4 (Phase 4 study) | China |